natgillin/translations-raw huggingface dataset:
Parkinson's disease (PD); sporadic or heritable dementia with Lewy bodies (DLB); pure autonomic failure (PAF) with a-synuclein deposition; multiple system atrophy (MSA); hereditary neurodegeneration with brain iron accumulation; and incidental Lewy body disease of advanced age. 
Parkinsonova bolest (PD), sporadična ili nasljedna demencija sa Levijevim tijelima (sporadic or heritable dementia with Lewy bodies - DLB), čisti autonomni poremećaj (pure autonomic failure - PAF) sa taloženjem a-sinukleina, multipla sistemska atrofija (MSA), nasljedna neurodegeneracija sa taloženjem željeza u mozgu, i sporadično oboljenje Levijevih tijela u poodmakloj životnoj dobi.
The device of claims 1-5 or the use of claims 6-11 wherein the sponges have a depth of 0.5cm. 
Naprava iz patentnih zahtjeva 1-5 ili uporaba iz patentnih zahtjeva 6-11 pri čemu spužve imaju dubinu od 0.5 cm.
The conjugate of claim 9, wherein the detectable moiety is selected from the group consisting of: 
Konjugat prema patentnom zahtjevu 20 ili 21, naznačen time što je detektabilni fragment odabran sa liste koja se sastoji od:
The threads are sized to engage the threads that are on the plurality of the containers 101, 1100 that are described herein. 
Navoji su takve veličine da zahvaćaju više navoja smještenih na posudama 101, 1100 koje su ovdje opisane.
The crystalline sodium salt according to claim 2, having an X-ray powder diffraction pattern comprising a peak at 10.1 degrees 2θ (± 0.2 degrees 20) when measured using CuKa radiation. 
Kristalna natrijeva sol prema zahtjevu 2, naznačena time, da ima uzorak difrakcije praha X-zraka koji obuhvaća vršnu vrijednost na 10,1 stupnjeva 20 (+ 0,2 stupnjeva 20) kada se mjeri uporabom radijacije CuKa.
The oligonucleotide for use according to any of claims 1-5, wherein: 
Spoj za upotrebu prema zahtjevu 1, pri čemu je životinja čovjek.
As can be seen in Figure 3, bottle 20 can have an opening 26 in end 22 through which the water and inoculant can be inserted into bottle 20 and mixed (by shaking or other methods), or a pre-mix of water/inoculant could be inserted into bottle 20. 
Kao što se vidi na slici 3, boca 20 može imati otvor 26 na kraju 22 kroz koji se voda i inokulant mogu HR P20060161 T3 unijeti u bocu 20 i miješati (trešnjom ili drugim postupcima), ili se neka prethodna mješavina vode i inokulanta može unijeti u bocu 20.
Use of a combination according to claim 31 in the manufacture of medicaments for use in the treatment of cancers. 
Kombinacija u skladu s patentnim zahtjevom 46, naznačena time, da je za uporabu u liječenju karcinoma.
A pharmaceutical composition or article of manufacture according to claim 25, comprising m-cresol at a concentration of at or about 0.3% (mass/mass solvent). 
Farmaceutski pripravak ili pripravak prema zahtjevu 25 naznačen time da sadrži m-kresol u koncentraciji od točno ili oko 0.3% (masa/masa otapala).
The pharmaceutical composition according to claim 1 formulated for oral, parenteral or rectal administration or suited to administration by inhalation or insufflation. 
Polipeptid za uporabu sukladno zahtjevu 8, naznačen time, da je navedeni farmaceutski pripravak formuliran za oralnu, parenteralnu, rektalnu upotrebu, inhalacijsku ili upuhivanjem.
reacting a compound of formula (I) with an intermediate of formula (11) by nucleophilic substitution of the fluoride at the ring position of a compound of formula (I) (herein referred to as Step 9) wherein 
reakciju spoja s formulom (I) s intermedijerom s formulom (11) nukleofilnom supstitucijom fluorida na položaju prstena spoja s formulom (I) (ovdje se naziva Korak 9) pri čemu
breweries or wineries. 
do pivovara ili vinarija.
Oligo comprises poly (2,2 dimethyl-1-3-propylcarbonate) (PCN) polyol having a theoretical molecular weight of from 500 to 3,000 Daltons; 
[image] pri čemu Oligo sadrži polikarbonat poliol koji ima teorijsku molekulsku masu od 500 do 3000 Daltona
A compound according to claim 1 or claim 2 for use in the prophylaxis or treatment of cancer. 
Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 za uporabu u profilaksi ili liječenju raka.
Further hydrolysates may be used in the frame of the present invention, as long as they are not derived from animal sources. 
Nadalje u okviru predstavljenog izuma mogu se koristiti hidrolizati, pod uvjetom da nisu podrijetlom iz životinjskih izvora.
The syringe of claim 1, characterized in that the one or more inwardly projecting flanges (120) have the apex point (121) configured for guiding one or more pins on the head portion of the piston into the guide path. 
Å trcaljka prema zahtjevu 1, naznačena time da jedna ili više prema unutra stršećih prirubnica (120) ima vršnu točku (121) konfiguriranu za vođenje jedne ili više igala na glavnom dijelu klipa u put za vođenje.
A transgenic murine mammal according to claim 6, wherein said means comprises a promoter selected from the group of CD19, CD20, µHC, VpreB1, VpreB2, VpreB3, λ5, Iga, IgB, kLC, λLC, and BSAP (Pax5). 
Transgeni murinski sisavac prema zahtjevu 6, naznačen time, da spomenuto sredstvo sadrži promotor odabran iz skupine od sljedećih: CD19, CD20, uHC, VpreB1, VpreB2, VpreB3, λ5, Iga, IgB, kLC, λLC i BSAP (Pax5).
Suitable monosaccharides include, but are not limited to, any of several simple open or closed chain sugars (in the L or D configuration), typically having 5 or 6 carbons (a pentose monosaccharide or a hexose monosaccharide), as well as 7 carbons (heptose monosaccharide). 
Prikladni monosaharidi uključuju, ali bez ograničenja, bilo koji od jednostavnih otvorenih ili zatvorenih lanaca šećera (u L ili D konfiguraciji), tipično s 5 ili 6 ugljikovih atoma (pentozni ili heksozni monosaharidi), kao i sa 7 ugljikovih atoma (heptozni monosaharidi).
Exemplary reagents and procedures for these reactions appear hereinafter and in the working examples. 
Primjeri reagensa i postupaka za ove reakcije pojavljuju se ovdje poslije i u radnim primjerima.
is a 6-membered heteroaryl ring, unsubstituted or substituted by 1 to 5 substituents individually selected from the group consisting of OH, halogen, cyano, C1-6-alkyl, C1-6-alkoxy, halogen-C1-6-alkyl, halogen-C1-6-alkoxy and hydroxy-C1-6-alkyl; 
je 6-člani heteroaril-prsten, nesupstituiran ili supstituiran s 1 do 5 supstituenata pojedinačno odabranih iz skupine koju čine: OH, halogen, cijano, C1-6-alkil, C1-6-alkoksi, halogen-C1-6-alkil, halogen-C1-6-alkoksi i hidroksi-C1-6-alkil;
A compound of any one of claims 1-13 or a composition of claim 14 for use in treating cystic fibrosis. 
Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva za upotrebu u liječenju cistične fibroze.
The generator may advantageously comprise a constriction portion through which the liquid medium is forced to flow, the constriction portion having a converging section of reducing cross-sectional area, a throat section and a diverging section of increasing cross-sectional area. 
Uređaj kao što je navedeno u bilo kojem prethodnom zahtjevu naznačeno time da generator mjehurića sadrži suženi dio kroz koji je tekući medij prisiljen teći, suženi dio imajući konvergentni odjeljak smanjujuće poprečno presječene površine, vratni odjeljak i divergentan odjeljak povećavajuće poprečno presječene površine.
and stereoisomers or pharmaceutically acceptable salts thereof. 
i njihovih stereoizomera ili njihovih farmaceutski prihvatljivih soli.
The residue was purified by ion exchange chromatography (Bio-Rad AG 50W-X8, [Trade Mark], 200-400 mesh, cation form, 40 g) eluting with dioxane initially followed by 2% pyridine in water. 
Ostatak se prečisti jonoizmjenjivačkom kromatografijom (Bio-Rad AG 50W-X8 (Trgovačko ime), 200-400 meša, kationski oblik, 40 g), eluiranjem s dioksanom na početku i onda s 2% piridinom u vodi.
Further characteristics and advantages of the invention will become better apparent from the description of some preferred but not exclusive embodiments thereof, illustrated by way of non-limiting example in the accompanying drawings, wherein: 
Sljedeća svojstva i prednosti predmetnog izuma pojasnit će se opisom nekih poželjnih, ali ne 1 isključivih utjelovljenja predmetnog izuma, koja su ilustrirana neisključivim primjerom u priloženim nacrtima:
A method of treating an individual with cancer associated with aberrant Notch signaling comprising administering to the individual an effective amount of an antibody that binds human Jagged1, wherein the antibody comprises: 
Izolirano protutijelo koje se veže na humani Jagged1, naznačeno time, da se protutijelo sastoji od HVR-H1 koji sadrži aminokiselinski slijed IDENTIFIKACIJSKOG BR.
The method according to claim 1, wherein natural raw materials selected from the group consisting of limestone, bauxite, clay/claystone, basalt, kimberlite, dunite, periodite, ingnimbrite, carbonatite, anhydrite, gypsum, and mixtures thereof, and/or industrial byproducts selected from the group consisting of waste dump materials, red mud, brown mud, landfill materials, ash, slag, ceramic residues, sulfate plant muds, phosphogypsum, and mixtures thereof are selected as sources for CaO, Al2O3(Fe2O3), SiO2 and SO3 for the raw meal mixture. 
Postupak sukladno zahtjevu 1, naznačen time što prirodne sirovine, kao što su vapnenac, boksit, glina / glinenac, bazalt, kimberlit, ingnimbrit, karbonatit, anhidrit, gips, itd 1 / ili industrijski nusproizvodi, kao što su odlagališni i otpadni materijal, pepeo i šute visoke 1 niske kvalitete, keramički ostaci, sulfati biljaka 1/ ili fosfogipsa, izabrani su kao izvor za CaO, AbO:;(Fe20:), $1021 SO3,
The waste trap (10) of any preceding claim, wherein the housing inlet surface (24) defines a maximum inlet diameter and a portion of the housing body (18) defines a body diameter, the maximum inlet diameter being less than the body diameter. 
Sifon (10) prema bilo kojem od prethodnih patentnih zahtjeva, gdje ulazna površina (24) kućišta definira maksimalan ulazni promjer i dio tijela (18) kućišta definira promjer tijela, maksimalan ulazni promjer je manji nego promjer tijela.
In one embodiment, concentrate crude material (CMM) (Example 1, FIG. 1) containing IL-18BP was applied into a MEP HYPERCEL® pre-equilibrated column (buffer (PBS) at pH 7.2). 
Prema jednoj izvedbi izuma, koncentrirani sirovi materijal (CMM) (Primjer 1, Slika 1) koji je sadržavao IL-18BP nanesen je na prethodno ekvilibriranu (pufer PBS pri pH 7.2) kolonu MEP HyperCel.
A compound according to any of claims 1 to 13 for use in treating a chemokine mediated disense, wherein the chemokine binds to an IL-8 a or B receptor in a inammal. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što je namijenjen upotrebi u liječenju bolesti uzrokovane kemokinima, naznačen time što se kemokin veže na receptor IL-8 a ili B kod sisavca.
Purify by silica gel chromatography (120 g) eluting with a gradient of 30% to 60% ethyl acetate in methylene chloride. 
To se pročisti kromatografijom na silikagelu (120 g), uz eluiranje gradijentom od 30 % do 60 % etil-acetata u metilen-kloridu.
R is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted lower heteroaryl. 
R* je odabran iz skupine koja se sastoji od nesupstituiranog C, alkila, supstituiranog ili nesupstituiranog arila, supstituiranog ili nesupstituiranog heteroarila, -supstituiranog ili nesupstituiranog heterocikloalkila, supstituiranog ili nesupstituiranog ari((C1.4 alkila), supstituiranog ili nesupstituiranog heteroarila(C;.4 alkila) i supstituiranog ili nesupstituiranog heterocikloalkil(C;.s alkila);
The use of the thermoplastic film of any of the first to fifteenth or twentieth numbered embodiments, or the product of any of the sixteenth to nineteenth numbered embodiments, for packaging. 
Uporaba termoplastične folije 1z bilo kojeg od zahtjeva 1 do 101ili 12, ili proizvod iz zahtjeva 11, za pakiranje, za primjenu silaže 1li za ručno pakiranje.
Use of a Ribosomal Protein Extract and optionally a Th1-promoting adjuvant for the preparation of a medicament for the treatment or prevention of a parasitic disease in a subject. 
Uporaba u skladu s patentnim zahtjevom 1, pri čemu je lijek za liječenje ili prevenciju lišmanijaze kod subjekta.
the reaction of a compound of formula (II) in the presence of a compound of formula (III); or 
reakcija spoja formule (II) u prisutnosti spoja formule (III);
The apparatus of claim 1, wherein the first release device is configured to vaporize or gasify the first substance associated with the first cartridge. 
E-cigareta (100) sukladno patentnom zahtjevu 1, naznačena time što je uređaj za prvo oslobađanje (118) konfiguriran za isparavanje ili uplinjavanje prve tvari povezane s prvim spremnikom (114).
No. 6,028,091. Forms which are frequently mentioned are sartans, such as candesartan, eprosartan, irbesartan, losartan, olmesartan, tasosartan, telmisartan or valsartan. 
Sartan za uporabu prema zahtjevu 1, naznačen time, da je sartan odabran iz skupine koju čine: kandesartan, eprosartan, irbesartan, losartan, tazosartan, telmisartan, valsartan i njihova farmaceutski prihvatljiva sol.
introducing positive charge carriers into the first layer. The solar cell according to claim 14, wherein the method of making the solar cell further comprises doping the second layer with at least one second element selected from the group consisting of N, Sb, Bi, C, O, Al, In, Tl, Cu, V, W, Fe, and Cr, and any combinations thereof. The solar cell according to claim 14, wherein the method of making the solar cell further comprises introducing the positive charge carriers into the first layer by deposition of positive charges on the front side n-doped area of the solar cell. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time što drugi sloj (26) se dopira najmanje jednim elementom iz skupine koju čine P, N, Sb, Bi, C, O, B, AL Ga, In, TI, Cu, V, W, Fe, Cr. HR P20180062 T1 Postupak u skladu s patentnim zahtjevom 13, naznačen time što u prvi sloj (22) se uvodi nosioce naboja odlaganjem pozitivnih naboja na prednjoj strani solarne ćelije (10, 100, 110), na temperaturi T2, gdje 10%C < T, < 600%, gdje se osobito pozitivne naboje odlaže na prednjoj strani solarne ćelije koronarnim izbojem.
Prior to the polymerization, the aqueous solution of the allylamine is emulsified in a suitable organic solvent with a suitable surfactant or mixture of surfactants. 
Postupak prema bilo kojem od zahtjeva 1-5, naznačen time da nadalje sadrži dodavanje u reakcijsku mješavinu barem pogodnog surfaktanta.
The humanized anti-CD40 antibody for use as in claim 4, wherein the disease or disorder is selected from the group consisting of: graft v. host disease, autoimmune or inflammatory disease, and CD40-expressing cancer. 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 2, naznačeno time što se bolest ili poremećaj bira iz skupine koju čine: reakcija presatka prema domaćinu, autoimuna ili upalna bolest, te rak koji eksprimira CD40.
The anti-Factor D antibody or antigen-binding fragment thereof of claim 1, wherein the light chain variable domain comprises: CDR-L1 having the amino acid sequence of SEQ ID NO: 16; CDR-L2 having the amino acid sequence of SEQ ID NO: 24; and CDR-L3 having the amino acid sequence of SEQ ID NO: 19, and the heavy chain variable domain comprises CDR-H1 having the amino acid sequence of SEQ ID NO: 25; CDR-H2 having the amino acid sequence of SEQ ID NO: 14; and CDR-H3 having the amino acid sequence of SEQ ID NO: 20. 
varijabilnu domenu lakog lanca, koja sadrži aminokiselinski slijed SEQ ID NO:9, gdje je CDR1 definiran sa SEQ ID NO:16, CDR2 je definiran sa SEQ ID NO:21, a CDR3 je definiran sa SEQ ID NO:22; i varijabilnu domenu teškog lanca, koja sadrži aminokiselinski slijed SEQ ID NO:10, gdje je CDR1 definiran sa SEQ ID NO:23, CDR2 je definiran sa SEQ ID NO:14, a CDR3 je definiran sa SEQ ID NO:20; ili
The public sanitary device as claimed in claim 1, wherein the housing comprises two or more walk-in positions, wherein at least one of the walk-in positions is provided with the door and at least one of the walk-in positions is not provided with the door. 
Javni sanitarni uređaj prema zahtjevu 1, pri čemu kućište ima dva ili više položaja u ravnini poda, pri čemu je najmanje jedan od položaja (20) u ravnini poda opremljen vratima i najmanje jedan od položaja (30) u ravnini poda nije opremljen vratima.
Rifamycin SV, which has been known since the 1960s, is a semi-synthetic active ingredient which is derived from rifamycin S and which has a strong antimicrobial and/or anti-infectious activity both locally and parenterally. 
Rifamicin SV, poznat od 1960-ih, je polusintetički aktivni sastojak nastao od Tifamicina S a koji ima jako antimikrobno iili antiinfektivno djelovanje i lokalno i parenteralno.
The resulting mixture was stirred at room temperature for 16h. 
Dobivenu smjesu miješa se 16 sati na sobnoj temperaturi.
The potent effect of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride in both experiments demonstrated its strong inverse agonist activity. 
Snažan učinak 1-[3-[3-(4-klorfenil)propoksilpropil]-piperidin moncklorida u obim eksperimentima demonstrirao je njegovo snažno djelovanje kao inverznog agonista.
The front wall of the box has two additional side walls, whereat the side walls are shorter than the front wall and the additional side walls have extrusion ridges or have no extrusion ridges. 
Prednji zid kutije ima dva dodatna bočna zida, gdje su bočni zidovi kraći od prednjeg zida i dodatni bočni zidovi imaju prijelome, u obliku izbočenja ili nemaju prijelome u obliku izbočenja.
iii) optionally separating the stereoisomers by known methods, e.g. chiral HPLC chromatography. The compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical. 
Spoj prema zahtjevu 1 u obliku slobodne baze ili farmaceutski prihvatljive kiselinske adicijske soli, naznačen time, da se koristi kao farmaceutsko sredstvo.
and the resulting mixture stirred for 3 days at room temperature. 
i dodavana smjesa se miješa 3 dana na sobnoj temperaturi.
a step of hybridization of at least one segregant X with at least one segregant Y, the segregant X converting at least 60% of xylose to ethanol in 60 hours and/or the segregant Y having a delay of initiation of alcoholic fermentation of less than 30 hours, so as to obtain at least one hybrid. 
- koraku hibridiziranja najmanje jednog segreganta X s najmanje jednim segregantom Y, gdje navedeni segregant X prevodi najmanje 60% ksiloze u etanol u 60 sati i/ili navedeni segregant Y ima kašnjenje početka alkoholne fermentacije manje od 30 sati, kako bi se dobilo najmanje jedan hibrid.
a group of formula —N2X, wherein X represents a suitable negatively-charged counterion (such as Br4−); or 
spoj formule -N>X, pri čemu X predstavlja pogodni negativno naelektrizirani suprotni ion (kao što je BF*");ili
Aqueous compositions comprising the microaggregates can be lyophilised prior to distribution. 
Vodeni sastavi koji sadrže mikroagregate mogu se liofilizirati prije distribucije.
E is a methyl linker which is substituted by aminomethyl, wherein the amino group of the aminomethyl is unsubstituted, or mono- or disubstituted by LA, or E is a methyl linker which is substituted by (azetidin-1-yl)methyl, 
YjeNili CH, E je metilna poveznica koja je supstituirana s aminometilom, pri čemu je amino skupina od aminometila nesupstituirana, ili mono- ili disupstituirana s LA, ili E je metilna poveznica koja je supstituirana s (azetidin-1- il)metil,
The method of claim 16, further comprising administering at least one second therapeutic agent selected from the group consisting of a HCV antiviral agent, an immunomodulator, and an anti-infective agent. 
Kombinacija spojeva prema bilo kojem od patentnih zahtjeva 1 do 9 ili njegove farmaceutski prihvatljive soli ili hidrati, naznačena time što se sastoji i od najmanje jednog drugog terapeutskog sredstva koje je izabrano od HCV antivirusnih sredstava, imunomodulatora i anti-infektivnih sredstava.
For acute myelogenous leukemia, commence after autologous stem cell transplantation or after chemotherapy. 
Kod akutne mijeloične leukemije započeti terapiju nakon autologne transplantacije koštane srži ili nakon
It is anyway quite clear that, if it fails to be cleaned frequently, it may well give rise to the same kind of drawbacks as already discussed with reference to EP-A-0 521 510. 
Ionako je prilično jasno da ako ga se ne čisti često, to vrlo lako može dovesti do istog tipa nedostataka, što je već rečeno u vezi s dokumentom EP-A-0 521 510.
The titled compound is prepared analogously to 4-fluoro-3-methoxy-benzenesulfonyl chloride (Intermediate 102a) by replacing 4-fluoro-3-methoxyaniline with 4-chloro-3-fluoro-phenylamine. 
Naslovni spoj je proizveden analogno 4-fluor-3-metoksi-benzensulfonil kloridu (intermedijat 1024) zamjenom 4-fluor-3-metoksianilina sa 4-klor-3-fluorfenilaminom.
Optionally, the tablets can be coated with conventional materials used for film coating, i.e. as described in Pharmaceutical Coating Technology, 1995, edited by Graham Co le. 
Po želji, tablete mogu biti obložene uobičajenim materijalima koji se koriste za oblaganje filmom, kako je na primjer opisano u Pharmaceutical Coating Technology, 1995., urednik Graham Cole.
Such drawback is greater in the case of users which are children, whose foot typically has dimensions which increase in relatively short times. 
Takav nedostatak je veći u slučaju djece kao korisnika, čije dimenzije stopala se tipično povećavaju u relativno kratkom vremenu.
Composition according to claim 2, wherein the andrographolides are andrographolide, 14-deoxy-11,12-didehydroandrographolide, and neoandro-grapholide. 
Pripravak prema patentnom zahtjevu 2, naznačen time da andrografolidi jesu andrografolid, 14-deoksi-11,12-didehidroandrografolid te neoandrografolid.
wherein R is as defined in claim 1 . A process according to claim 1, wherein compound (I-a′) is obtained by slow addition, under stirring, of gaseous bromine to a solvent-free equimolar amount of compound (I′-c), at 0-10° C.: 
Postupak prema zahtjevima I ili 6, gdje se spoj (T'-a) dobiva sporim dodavanjem plinovitog broma, uz miješanje, ekvimolarnoj količini spoja (I -c) bez otapala, kako je definirano u zahtjevu 13, na 0 - 10%C.
In some embodiments, not more than 10% of the proton pump inhibitor is released in an acid stage (900 ml 0.1N HCl at 100 rpm, pH1), and not less than 75% of the proton pump inhibitor is released in an in vitro dissolution assay (900 ml phosphate buffer pH 6.8 at 100 rpm) at 45 minutes following the acid stage. 
(a) otpuštanje najviše 10 % prema težini inhibitora protonske pumpe tijekom 120 minuta u kiseloj fazi s 900 ml 0,1 N HCI pri 100 o/min te (b) otpuštanje najmanje 75 % prema težini inhibitora protonske pumpe tijekom 45 minuta u 900 ml fosfatnog pufera pH vrijednosti 6,8 pri 100 o/min nakon primjene kiseline.
In another preferred embodiment of the pharmaceutical methods and means of the invention, the pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct is to be administered by continuous infusion for at least four weeks followed by a 2-week treatment-free interval. 
Konstrukt za uporabu prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što se farmaceutski pripravak koji sadrži CD19xCD3 konstrukt protutijela bispecifičnog jednostrukog lanca treba davati kontinuiranom infuzijom najmanje četiri tjedna nakon čega slijedi interval od 2 tjedna bez tretmana.
Methyl oxalyl chloride (0.386 ml, 4.2 mmol) is added and the resulting suspension is stirred at room temperature overnight. The reaction mixture is cooled (0 °C) and quenched dropwise with methanol (10 ml). 
Doda se metil oksalil klorid (0,386 ml, 4,2 mmola) i dobivenu suspenziju se miješa preko noći pri sobnoj temperaturi, Reakcijsku smjesu se ohladi (0*C) i razrijedi kap po kap s metanolom (10 ml).
The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein X is N. 
Farmaceutski sastav prema zahtjevu 1 ili 2, pri čemu X je N.